Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’. The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device capable of non-invasive detection of pre-symptomatic respiratory infectious disease.

Warfighters routinely operate in remote environments where access to medical personnel is limited and the ability to diagnose infectious disease early is challenging. Under these conditions, the risk of contracting a respiratory disease, and subsequently its spread to other personnel, is high and can have a severe impact on mission readiness. Most current diagnostic testing platforms are unsuitable to be deployed in the field, and so there is a significant need for a portable solution.

The portable device by Owlstone will be adapted to work off battery power and detect VOCs present in exhaled breath, filling a gap in infectious disease detection. By aiming for the earliest possible identification of asymptomatic infected individuals in the field, the device would reduce the risk of disease transmission wherever deployed, providing a strategic advantage to the force.

Based on the Company’s proprietary FAIMS technology, the device will be developed over a two-year period, supported by clinical studies to be performed at Duke University. Initial work will focus on identifying and validating breath biomarkers for viral and bacterial pathogens and defining performance requirements for the device.

If successful, there is potential for a second phase to the project for further development of the device to the point of being ready for high-volume manufacturing by Owlstone, and global deployment in the field.

“We have completed multiple studies in lung inflammation and bacterial and viral infectious disease (including COVID) with major pharma and academic partners, providing us with a broad list of candidate biomarkers for consideration in this project. We have a proprietary technology in FAIMS, and extensive experience with device development and sensor design, including in small handheld devices. With proven expertise and technology in both areas, we believe Owlstone is uniquely positioned to support the EXHALE project and are pleased that the DIU agrees and has awarded us this contract.” 

Billy Boyle, co-founder and CEO at Owlstone Medical

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Owlstone Medical Ltd. (2023, June 05). Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection. News-Medical. Retrieved on October 10, 2024 from https://www.news-medical.net/news/20230517/Owlstone-Medical-Wins-Contract-from-US-Department-of-Defense-to-Develop-Handheld-Breath-Biopsy-Device-for-Early-Infectious-Disease-Detection.aspx.

  • MLA

    Owlstone Medical Ltd. "Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection". News-Medical. 10 October 2024. <https://www.news-medical.net/news/20230517/Owlstone-Medical-Wins-Contract-from-US-Department-of-Defense-to-Develop-Handheld-Breath-Biopsy-Device-for-Early-Infectious-Disease-Detection.aspx>.

  • Chicago

    Owlstone Medical Ltd. "Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection". News-Medical. https://www.news-medical.net/news/20230517/Owlstone-Medical-Wins-Contract-from-US-Department-of-Defense-to-Develop-Handheld-Breath-Biopsy-Device-for-Early-Infectious-Disease-Detection.aspx. (accessed October 10, 2024).

  • Harvard

    Owlstone Medical Ltd. 2023. Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection. News-Medical, viewed 10 October 2024, https://www.news-medical.net/news/20230517/Owlstone-Medical-Wins-Contract-from-US-Department-of-Defense-to-Develop-Handheld-Breath-Biopsy-Device-for-Early-Infectious-Disease-Detection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Owlstone Medical Presents Data Demonstrating Progress in Development of Breath Biopsy Test for the Early Detection of Lung Cancer